

























































battery	 of	 molecular	 inquiries	 which	 included	 lipidomic	 and	 proteomic	 screens,	 as	 well	 as	
hypothesis-driven	biochemistry.	The	results	of	this	comprehensive	investigation	include	the	first	
characterization	 of	 the	murine	 CSF	 lipidome	 and	 the	 deepest	 characterization	 to	 date	 of	 the	
murine	CSF	proteome.		
	











Most	 importantly,	 an	unbiased	proteomic	 screen	of	CSF	 collected	 from	mice	with	a	 selective	
knock	out	of	VPS35	 in	 forebrain	neurons	(engineered	using	the	Camk2a	 system)	uncovered	a	
total	of	71	hits	(52	parametric	and	19	nonparametric)	from	the	1505	proteins	detected.	Pathway	




tau,	 and	 importantly,	 that	 these	 events	 occur	 independent	 of	 cell	 death.	 Further,	 we	 find	
evidence	of	convergence	of	these	pathways	in	both	mouse	and	human	CSF.	However,	as	these	
BACE1	 substrates	 likely	 accumulate	 in	 plaques,	 we	 propose	 CSF	 total	 tau	 as	 a	 biomarker	 of	
endosomal	dysfunction	with	utility	over	the	entire	course	of	AD	progression.		
	
We	 have	 identified	 and	 validated	 a	 series	 of	 in	 vivo	 biomarkers	 that	 are	 reflective	 of	 AD-
associated	endosomal	dysfunction.		While	clearly	sensitive	to	this	cellular	pathology,	future	work	
is	required	to	determine	their	specificity.		Additionally,	follow-up	studies	are	required	to	show	




































































































































































































accuracy	 and	 therapeutic	 intervention.	 Nevertheless,	 AD	 is	 broadly	 categorized	 into	 two	









this	 sex-based	 discrepancy	 remains	 unclear,	 although	 social	 (e.g.	 inequitable	 educational	












































the	 post-mortem	 brain	 of	 a	 patient	 with	 severe	 memory	 defects,	 he	 noticed	 abnormal	






















constellation	 of	 symptoms	 and	 many	 of	 these	 symptoms	 are	 shared	 among	 other	 types	 of	
transient	 or	 progressive	 neuropathies,	 rendering	 behavioral	 criteria	 alone	 insufficient.	 In	 the	
early	1990s,	nearly	90	years	after	its	recognition	as	a	disease,	a	cerebrospinal	fluid	(CSF)-based	










































terminal	 fragment	 (C83	or	a-CTF).	Amyloidogenic	 cleavage	begins	with	 cleavage	by	BACE1	 to	






(BACE1)	and	a	g-secretase	 complex,	 yielding	a	peptide	of	either	40	amino	acids	 (Ab40)	or	42	
amino	acids	(Ab42)	depending	on	the	site	of	gamma	cleavage.	Studies	have	shown	that	Ab42	is	





This	 leading	 theory	 of	 AD	pathogenesis	 asserts	 that	 the	 accumulation	 of	 Ab42	 is	 the	 central,	
initiating	event	which	gives	rise	to	all	subsequent	pathology.	Though	various	aggregate	forms	of	






promotes	 a	 cascade	 of	 cytotoxic	 effects	 (Figure	 1.4)	 which	 include	 tau	 dysregulation,	
neurofibrillary	tangle	formation,	and	ultimately	neuronal	death.	Several	details,	however,	remain	
unclear.	For	example,	debate	has	ensued	regarding	which	aggregate	form	of	Ab42	(monomeric,	
oligomeric,	 or	 deposited	 plaque)	 contribute	most	 to	 disease	 pathology	 (Walsh,	 Klyubin	 et	 al.	
2002,	Glabe	 2006),	 and	 in	 general,	 the	mechanism	 through	which	 these	 events	 promote	 tau	
dysregulation	(Zheng,	Bastianetto	et	al.	2002,	Manczak	and	Reddy	2013,	Bloom	2014).		
	
The	 amyloid	 hypothesis	 is	 strengthened	 by	 several	 key	 findings.	 First,	 autosomal	 dominant,	
disease-causing	mutations	in	APP	and	gamma-secretase	presenilins	PSEN1	and	PSEN2	have	been	
identified	 (Levy-Lahad,	Wasco	 et	 al.	 1995,	 Sherrington,	 Rogaev	 et	 al.	 1995).	 The	 pathogenic	
impact	of	these	mutations	is	attributed	to	increased	Ab42	generation	through	either	an	increased	
production	of	Ab	 (both	Ab40	and	Ab42)	altogether	or	an	 increase	 in	 the	ratio	of	Ab42/Ab40.	
Second,	Down’s	Syndrome	patients	are	at	substantially	higher	risk	for	AD,	with	more	than	half	
ultimately	 developing	 the	 disease.	 This	 has	 been	 attributed	 to	 the	 extra	 copy	 of	 APP	 (on	
chromosome	21),	 and	 therefore	 substantially	 elevated	 levels	 of	 its	metabolic	 products	which	










Yet,	 despite	 its	 rise	 as	 the	predominant	 theory	 of	AD	pathogenesis	 in	 the	 past	 two	decades,	
several	 challenges	 to	 the	 amyloid	 hypothesis	 remain.	 First,	 there	 is	 an	 anatomical	mismatch	
between	extracellular	plaques	and	neurotoxicity	in	AD	brains.	Specifically,	the	medial	temporal	
lobe,	 which	 undergoes	 the	 primary	 and	 most	 extreme	 neurotoxicity	 (Khan,	 Liu	 et	 al.	 2014,	
Altmann,	Ng	et	al.	2015)	bears	 the	 least	plaque	burden	 in	 the	cortex	 (Braak	and	Braak	1991,	
Altmann,	Ng	et	al.	2015).	Second,	the	overall	deposition	of	Ab	in	the	AD	brain	does	not	correlate	
with	 cognitive	 decline;	 in	 fact,	 extensive	 amyloid	 plaques	 have	 been	 documented	 in	 non-
demented,	 cognitively	 ‘normal’	 individuals	 (Rentz,	 Locascio	 et	 al.	 2010).	 Third,	 other	




disease.	 One	 must	 consider	 that	 the	 failure	 of	 Ab-targeting	 therapies	 could	 derive	 from	
neurodegeneration	occurring	prior	to	intervention.	However,	taken	together,	these	observations	






Though	not	 considered	a	 canonical	biomarker	of	AD,	endosomal	dysfunction	has	 increasingly	
been	recognized	as	a	salient	feature	of	its	cytopathology.	Cataldo,	et	al.	described	an	abnormal	




with	 both	 sporadic	 (Israel,	 Yuan	 et	 al.	 2012)	 and	 autosomal-dominant	 forms	 of	 AD	 (Raja,	
Mungenast	et	al.	2016).	
	




2015).	As	 such,	 endosomal	 trafficking	has	 risen	as	one	of	 the	major	 categories	of	AD-related	








risk	 of	 AD.	 These	 genes	 broadly	 coalesce	 into	 four	 functional	 categories	 including	 endosomal	








Finally,	 expression	 profiling	 studies	 of	 post-mortem	 brain	 tissue	 have	 identified	 a	 significant	
reduction	of	endosomal	trafficking	proteins	(VPS35,	VPS26a,	and	Beclin-1)	and	lipids	(PI3P)	in	the	













also	 been	 demonstrated:	 that	 amyloidogenic	 APP	 processing	 can	 promote	 endosomal	
dysfunction	due	to	cytotoxic	effects	of	amyloidogenic	APP	products	(Jiang,	Mullaney	et	al.	2010,	












al.	 1997,	 Seaman,	 McCaffery	 et	 al.	 1998);	 its	 mammalian	 orthologs	 were	 identified	 shortly	




Seaman	 et	 al.	 demonstrated	 that	 retromer	 traffics	 receptor	 VPS10p	 along	 the	 retrograde	
pathway,	ensuring	continuous	delivery	of	its	ligand	carboxypeptidase	Y	(CPY)	from	the	TGN	to	
the	prevacuolar	endosome	 (Seaman,	Marcusson	et	 al.	 1997,	 Seaman,	McCaffery	et	 al.	 1998).	











proteins	 which	 must	 organize	 biochemically	 to	 traffic	 endosomal	 cargo	 to	 the	 appropriate	
destination	(Small	and	Petsko	2015).	These	modules	of	retromer	assembly	have	been	grouped	







and	 the	 retrograde	 pathway.	 (b)	 The	 five	 modules	 of	 retromer	 assembly	 include	 the	 cargo	
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either	 VPS26a	 or	 VPS26b),	 is	 an	 essential	 and	 unifying	 component	 of	 the	 retromer	 assembly	
(Figure	1.6b).	In	fact,	expression	of	these	core	proteins	is	often	tightly	regulated	within	the	cell,	






This	 core	 trimer	 is	 recruited	 to	 the	endosomal	membrane	 via	 components	of	 the	membrane	
recruiting	module,	which	can	include	proteins	such	as	sorting	nexin-3	(SNX3)	(Harterink,	Port	et	
al.	2011)	and	RAB7A	(Rojas,	van	Vlijmen	et	al.	2008,	Seaman,	Harbour	et	al.	2009,	Harrison,	Hung	


























George-Hyslop	 et	 al.	 2012).	 As	mentioned	 above,	 CIM6PR,	which	delivers	 cathepsin	D	 to	 the	
 18 
endolysosomal	system,	has	also	been	verified	as	a	retromer	cargo	(Arighi,	Hartnell	et	al.	2004,	
Seaman	2004).	 Finally,	 several	neuronal	 signaling	 (GluR1	 (Temkin,	Morishita	et	al.	2017))	and	





Retromer	was	 first	 linked	 to	 AD	 by	 our	 lab	 in	 2005	 through	 a	microarray	 experiment	which	











that	 retromer	 deficiency	 (via	 knockdown	 of	 VPS35	 or	 VPS26a)	 can	 lead	 to	 increased	




the	majority	 of	 its	 amyloidogenic	 effects	 on	 APP	 (Small	 and	 Gandy	 2006)).	 This	 suggests	 an	













First,	 knockdown	 of	 retromer	 core	 proteins	 promotes	 Ab	 accumulation	 through	 increased	
retention	of	APP	and	BACE1	in	the	endosome	(Wen,	Tang	et	al.	2011,	Bhalla,	Vetanovetz	et	al.	
2012).	 Second,	 it	 results	 in	 an	 enlargement	 of	 endosomes	 (Offe,	 Dodson	 et	 al.	 2006,	 Bhalla,	
Vetanovetz	et	al.	2012),	purportedly	through	an	accumulation	of	cargo	at	the	limiting	membrane.	
Third,	 retromer	 deficiency	 disrupts	 delivery	 of	 protease	 cathepsin	 D	 to	 the	 endolysosomal	
system,	resulting	in	its	increased	extracellular	secretion	(and	increased	cathepsin	D	secretion	into	










































This	project	 involves	 the	 collection	of	CSF	and	brain	exosomes	 from	 retromer-deficient	mouse	
models	for	investigation	of	proteomic	and	lipidomic	changes	which	can	be	translated	to	human	





















recent	 development	 of	 two	 critical	 techniques	 position	 brain-derived	 exosomes	 as	 a	 feasible	












We	 have	 amassed	 an	 assortment	 of	 retromer-deficient	mouse	models,	 distinct	 in	 either	 the	
deleted	cargo	recognition	core	protein	or	in	the	region	of	genetic	defect	(Figure	1.8).	The	Camk2a	
knockout	models	(VPS35	and	VPS26a),	restrict	retromer	deficiency	to	forebrain	neurons.	And	the	

































Lipids	 comprise	 a	 diverse	 class	 of	 molecules	 which	 are	 critical	 for	 many	 aspects	 of	 cellular	






















LC-MS	 allows	 both	 qualitative	 and	 quantitative	 analyses	 and	 has	 shown	 great	 promise	 in	




CSF	 collection	 in	mice	 is	 not	 trivial.	 Roughly	 5uL	 of	 fluid	 can	 be	 extracted	 from	 each	mouse	
through	the	cisterna	magna	via	a	post-mortem	technique,	though	the	amount	can	vary	based	on	
a	multitude	of	factors	such	as	age,	gender,	and	diet.	Special	care	is	required	to	minimize	blood	












volume	 of	 30uL	 per	 biological	 replicate	 in	 order	 to	 boost	 the	 signal/noise	 ratio	 for	 the	 less	




We	 began	 our	 studies	 with	 the	 VPS26a-haploinsufficient	 mice	 for	 several	 reasons.	 First,	







Murine	 CSF	 collection	 is	 a	 highly-skilled	 procedure	 which	 requires	 much	 practice	 to	 yield	
consistent	results.	In	order	to	perform	lipidomic	investigations	of	murine	CSF,	we	first	needed	to	
ensure	 that	 we	 could	 collect	 high	 quality	 samples	 from	 our	 rodent	 models.	 As	 blood	
contamination	could	have	tremendous	impact	on	the	results	of	our	analyses	(due	to	the	distinct	
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threshold	 for	 visible	 contamination).	 Using	 these	 two	 criteria	 we	 are	 able	 to	 isolate	




















of	pooled	wildtype	agouti	CSF.	First,	 it	 is	worth	noting	 that	we	were	able	 to	detect	 signal	 for	
nearly	all	lipid	classes	that	are	present	in	human	CSF	and	that	their	overall	contribution	to	the	
CSF	 lipidome	 is	 remarkably	 similar	 to	 that	 of	 humans	 (Figure	 2.2a;	 results	 from	 independent	
runs).	The	limited	volume	(30uL	for	mice	versus	300uL	for	humans),	however,	 largely	restricts	
discovery	 to	 the	 most	 highly	 abundant	 lipid	 species	 (cholesteryl	 esters,	 free	 cholesterol,	
phosphatidylcholine,	 sphingomyelins,	 diacylglycerol,	 triacylglycerol,	 and	











lipid	 species	 (mol	 %);	 FC=free	 cholesterol;	 CE=cholesteryl	 ester;	 AC=	 acyl	 carnitine	 	 ;	





LPC=lysophosphatidylcholine;	 LPCe=lysophosphatidylcholine	 ether;	 NAPE=N-acyl	
phosphatidylethanolamine;		NSer=	N-acyl	serine.	(b)	Lipid	classes	are	further	broken	down	into	
the	individual	molecules	which	comprise	that	class.	Of	the	eighteen	cholesteryl	esters	identified	





We	 therefore	 applied	 this	 pooling	 approach	 to	 our	 investigation	 of	 CSF	 lipid	 changes	 in	 the	
VPS26a+/-	mice	(Figure	2.3).	High	quality	CSF	from	3-month-old	VPS26a+/-	males	and	littermate	
























(n=6);	 FC=free	 cholesterol;	 CE=cholesteryl	 ester;	 AC=	 acyl	 carnitine	 	 ;	 MG=monoacylglycerol;	
DG=diacylglycerol;	 TG=triacylglycerol;	 Cer=ceramide;	 dhCer=	 dihidroceramide;	
SM=sphingomyelin;	 dhSM=dihidrosphingomyelin;	 GalCer=galactosylceramide;	 Sulf=sulfatide;	
PA= phosphatidic	 acid;	 PC=phosphatidylcholine;	 PCEe=phosphatidylcholine	 ether;	
PS=phosphatidylserine;	 PI=phosphatidylinositol;	 PG=phosphatidylglycerol;	
BMP=bismonoacylglycerophosphate;	 AcylPG=acyl-phosphatidylglycerol;	
LPC=lysophosphatidylcholine;	 LPCe=lysophosphatidylcholine	 ether;	 NAPE=N-acyl	
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lipid	 category	 of	 interest	 instead	 of	 splitting	 into	 three	 modes.	 We	 were	 hopeful	 that	 this	
approach	 would	 compensate	 for	 the	 smaller	 volume	 available	 for	 this	 follow-up	 validation.	
Despite	 our	 efforts,	 however,	 we	 were	 unable	 to	 detect	 two	 of	 the	 sphingomyelin	 species	
(d18:1/26:0	 and	 d18:1/26:1)	 from	 the	 first	 cohort	 of	 pooled	 CSF.	 Among	 the	 remaining	 ten,	








was	 conducted.	 (a)	No	 changes	 in	 the	 positive	mode	 lipid	 classes	were	 observed.	 	 Values	 are	
normalized	to	total	lipid	content	and	then	to	the	wildtype	and	represent	the	mean	+/-	SEM	(n=6);	
Cer=ceramide;	 SM=sphingomyelin;	 dhSM=dihidrosphingomyelin;	 GalCer=galactosylceramide;	























reduced:	 sphingomyelins	 (SM),	 dihydrosphingomyelins	 (dhSM),	 and	 monohexosylceramides	
(MhCer).	 Values	 are	 normalized	 to	 the	wildtype	 and	 represent	 the	mean	 +/-	 SEM	 (n=3-5;	 *P-
value<0.05,	**P-value<0.01);	dhCer=	dihidroceramide;	Cer=ceramide;	LacCer= lactosylceramide;	
	GalCer=galactosylceramide;	 PC=phosphatidylcholine;	 PCEe=phosphatidylcholine	 ether;	
LPC=lysophosphatidylcholine;	LPCe=lysophosphatidylcholine	ether.	(b)	A	breakdown	of	individual	
sphingomyelin	species	reveals	reduction	of	 five	 lipids	 in	the	VPS26a+/-	CSF:	SM	d18:1/18:1,	SM	
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included	 reductions	 in	both	dihydrosphingomyelins	 and	monohexosylceramides	 (Figure	2.6a).	
Taken	 together,	 these	 studies	 indicate	 progressive	 sphingolipid	 dysregulation	 in	 the	 VPS26a-






difficult	 to	 speculate	 which	 cell	 type	 might	 be	 responsible	 for	 imparting	 these	 sphingoliid	
changes.	In	order	to	explore	this	in	vivo,	we	made	use	of	our	VPS26a	neuron-specific	knockout	
(via	 Camk2a-Cre	 recombinase).	 Since	 VPS26a	 deficiency	 in	 this	mouse	model	 is	 restricted	 to	
neurons,	a	comparison	of	CSF	lipidomics	from	the	two	VPS26a	models	can	indicate	whether	the	
sphingomyelin	dysregulation	is	driven	by	neuronal	retromer	deficiency	or	instead	by	other	cell	







    
Figure	 2.7	 Sphingomyelin	 alterations	 in	 VPS26a-haploinsufficient	 mice	 derive	 from	 non-
neuronal	origins.		
(a)	 VPS26a	 is	 expressed	 in	 many	 cell	 types	 in	 the	 brain	 (Zhang,	 Chen	 et	 al.	 2014).	 A	 global	
assessment	 of	 lipidomic	 changes	 reveals	 no	 changes	 in	 sphingomyelins	 (SM),	
dihydrosphingomyelins	(dhSMs),	or	monohexosylceramides	(MhCer)	in	the	VPS26a	Camk2a	mice,	






























is	 worth	 mentioning	 that	 pooling	 CSF	 from	 mice	 of	 the	 same	 genotype	 (30uL	 volume)	 was	
favorable	 over	 analyzing	 individual	 samples	 (7uL	 volume)	 in	 maximizing	 the	 number	 of	
quantifiable	 lipids	 (by	 20%	 in	 the	 case	 of	 sphingomyelins).	 In	 the	 end,	we	 deem	murine	 CSF	
lipidomics	a	feasible	means	of	biomarker	detection	in	at	least	half	of	the	human	CSF	lipidome.	
	
In	 this	 study,	we	 conclude	 that	 VPS26a	 haploinsufficiency	 alters	 the	 sphingomyelin	 profile	 in	










Determining	 the	 source	 of	 these	 sphingomyelin	 changes	 in	 the	 brain	 would	 require	 the	
generation	 of	 alternative	 cell	 type-specific	 knockdown	 models,	 or	 alternatively,	 in	 vitro	






































the	 development	 of	 a	 protocol	 for	 isolating	 adult	 mouse	 brain	 exosomes	 (Perez-Gonzalez,	
Gauthier	et	al.	2012,	Asai,	Ikezu	et	al.	2015)	allows	the	interrogation	of	rodent	models	of	disease,	
reducing	the	translational	hurdles	and	boosting	the	exosome	yield	over	conventional	cell	culture	















determined	 that	 gradient	 fractions	 4-7	 are	 enriched	 in	 exosomal	markers	 alix	 and	 flotillin-1,	










are	 positive	 for	 markers	 alix	 and	 flotillin-1	 with	 limited	 contamination	 from	 other	 cellular	
compartments	(golgi	as	measured	by	GM130	and	ER	as	measured	by	calnexin).	(c)	These	fractions	






Several	 groups	 have	 reported	 the	 presence	 of	 retromer	 cargo	 recognition	 core	 proteins	 in	
exosomes	 of	 various	 tissues	 or	 fluids	 (Gonzales,	 Pisitkun	 et	 al.	 2009,	 Demory	 Beckler,	
Higginbotham	 et	 al.	 2013,	 Skogberg,	 Gudmundsdottir	 et	 al.	 2013).	 Therefore,	 we	 wondered	
whether	we	could	detect	these	retromer	proteins	in	brain-derived	exosomes	of	adult	mice.	Using	
the	 technique	 described	 above,	we	 isolated	 exosomes	 from	 the	 brains	 of	wildtype	mice	 and	
probed	for	retromer	core	proteins	VPS35	and	VPS26a	(Figure	3.2a).	In	fact,	both	of	these	proteins	































exosomes.	 (b)	Mice	with	 neuron-specific	 deletion	 of	 VPS35	 (via	 Camk2a-Cre)	 show	decreased	
levels	 of	 other	 core	 proteins	 in	 both	 the	 brain	 and	 in	 brain-derived	 exosomes.	 Values	 are	














overall	 retromer	 levels.	 Therefore,	 we	 sought	 to	 investigate	 other	 functional	 readouts	 of	
retromer	deficiency	which	might	be	released	in	association	with	exosomes.		
	
APP,	 as	 described	 above,	 is	 a	 transmembrane	 protein	 which	 can	 be	 cleaved	 by	 several	
membrane-associated	 proteases	 in	 various	 cellular	 compartments.	 The	 resulting	 C-terminal	
fragments	(CTFs)	have	been	found	in	exosomes	from	cultured	cells	(Sullivan,	Jay	et	al.	2011),	as	
well	 as	 brain-derived	 exosomes	 (Perez-Gonzalez,	 Gauthier	 et	 al.	 2012).	 Retromer	 deficiency	
increases	retention	of	APP	in	the	endosome	(Bhalla,	Vetanovetz	et	al.	2012),	where	 it	 is	most	
likely	to	be	cleaved	by	BACE1	(Small	and	Gandy	2006),	and	endosomal	membrane	(bearing	the	





To	 this	 end,	we	 isolated	exosomes	 from	 the	 two	models	 described	above	and	 their	wildtype	
littermates	and	probed	the	samples	with	an	antibody	directed	toward	an	epitope	within	the	b-
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3.2.5	 Brain	 exosomes	 from	 retromer	 knockout	 mice	 have	 decreased	 levels	 of	 exosomal	
markers	alix	and	flotillin-1		
In	the	course	of	our	brain	exosome	studies,	we	happened	upon	an	entirely	unexpected	finding:	













As	 alix	 and	 flotillin	 are	 often	 used	 to	 confirm	 exosomal	 identity,	 we	wondered	whether	 the	
decrease	 in	these	proteins	 in	the	exosomal	 fractions	suggest	changes	 in	exosomal	biogenesis,	
and	possibly	 their	morphology.	Accordingly,	we	examined	 the	brain	exosomes	 from	retromer	
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overall	 retromer	 levels	 in	 the	 brain.	 We	 opted	 not	 to	 immediately	 pursue	 this	 finding	 for	























(ADAM10),	 BACE1,	 and	 g-secretase	 (nicastrin)	 have	 been	 detected	 in	 brain-derived	 exosome	
fractions	 (Perez-Gonzalez,	Gauthier	 et	 al.	 2012),	 one	must	 consider	 that	 CTFs	 from	 the	brain	
might	be	progressively	processed	throughout	their	transport	into	the	bloodstream.	And	third,	it	
remains	entirely	possible	that	exosomes	which	house	b-CTFs	simply	do	not	cross	the	blood-brain	
barrier.	 While	 a	 growing	 number	 of	 studies	 have	 shown	 delivery	 of	 exosomes	 from	 the	
bloodstream	 into	 the	 brain	 (Yang,	 Martin	 et	 al.	 2015,	 Khalyfa,	 Gozal	 et	 al.	 2017),	 few	 have	
described	the	reverse	transport	(Goetzl,	Boxer	et	al.	2015,	Goetzl,	Mustapic	et	al.	2016),	and	the	
mechanisms	 for	 exosomal	 traverse	 of	 the	 blood-brain	 remain	 largely	 unclear.	 (Whether	
exosomes	are	delivered	across	this	barrier	in	a	content-specific	manner	is	currently	unknown	but	
should	be	considered	as	one	potential	explanation	 for	 the	 lack	of	b-CTFs	 in	circulating	serum	
exosomes.)	 If	 either	 of	 the	 latter	 two	 possibilities	 are	 true,	 then	 continued	 work	 for	 the	
development	of	an	exosome-based	biomarker	should	be	strategized	to	overcome	the	challenge	
 56 




Finally,	we	report	an	unexpected	 finding:	 that	 retromer	deficiency	 in	vivo	may	alter	exosome	
biogenic	 pathways.	 This	 conclusion	 is	 supported	 by	 a	 decrease	 in	 exosome	markers	 alix	 and	
flotillin-1	 in	 the	 exosome	 fractions	 from	 retromer-deficient	 mice	 and	 a	 potential	 (as	 yet	
descriptive)	shift	in	exosome	size.	Recent	studies	by	other	labs	have	demonstrated	that	Alix	may	
be	 functionally	 regulated	 by	 Arf6	 (Ghossoub,	 Lembo	 et	 al.	 2014),	 which	 can	 also	 regulate	
retromer	 (Marquer,	Tian	et	al.	2016).	Though	the	directionality	of	 these	relationships	doesn’t	
clarify	 the	 observed	 transcriptional	 effects	 of	 retromer	 deficiency	 on	 alix	 in	 our	 studies,	 it	











(Rojas,	 van	 Vlijmen	 et	 al.	 2008,	 Tholen,	 Biniossek	 et	 al.	 2011,	 Tholen,	 Biniossek	 et	 al.	 2014).	




et	al.	1995,	Armstrong,	Mattsson	et	al.	2014).	 	Taken	together,	 these	observations	 lead	us	 to	








to	 maximize	 our	 biomarker	 discovery	 efforts	 in	 favor	 of	 hypothesis-driven	 immunoblotting	







(Huhmer,	 Biringer	 et	 al.	 2006,	 Schutzer,	 Liu	 et	 al.	 2010),	with	 albumin	 and	 immunoglobulins	
occupying	a	large	majority	of	the	total	(Yuan	and	Desiderio	2005).	Therefore,	as	in	the	lipidomics	










































Surprisingly,	 however,	 of	 all	 1215	 proteins	 detected,	 none	 were	 significantly	 altered	 in	 the	
VPS26a+/-	CSF	after	controlling	for	multiple	testing.	In	fact,	a	correlation	plot	of	the	log	ratios	for	












the	 multiple	 testing-corrected	 significance	 threshold).	 Among	 the	 handful	 of	 statistical	
candidates	were	 several	which	 have	 been	 previously	 linked	 to	 the	 endosomal	 system.	 These	
included	folate	receptor	1	(FOLR1),	GDNF	family	receptor	alpha	1	(GFRA1),	profilin	(PFN1),	and	
platelet-activating	factor	acetylhydrolase	1b3	(PAFAH1B3).	GFRA1	is	known	to	be	trafficked	by	
SORL1,	a	 retromer	 cargo,	out	of	 the	endosome	 (Glerup,	 Lume	et	al.	 2013).	 FOLR1	undergoes	
















CSF.	Due	 to	 the	 large	volume	required	per	 lane,	only	 two	biological	 replicates	were	used	per	
condition.	While	we	realize	this	small	sample	size	is	insufficient	for	most	biochemical	assays,	our	
goal	 was	 the	 identification	 of	 a	 distinctive	 biomarker	 of	 endosomal	 dysfunction.	 Thus,	 we	
reasoned	 that	 this	 follow-up	 validation	 (of	 pooled	 samples	 which	 should	 minimize	 variance	
among	 samples	within	 each	 genotype)	 should	 properly	 inform	on	 the	 purported	decrease	 of	
PAFAH1B3	in	the	CSF	of	these	mice.	Results	of	the	immunoblot	revealed,	however,	that	the	levels	







(n=2	 due	 to	 limited	 availability	 of	 CSF).	 Values	 are	 first	 normalized	 to	 ponceau	 and	 then	 the	
wildtype	average	and	represent	the	mean	+/-	SEM.		
	




























labeled	with	a	distinct	 isobaric	TMT	 tag,	 combined,	and	 fractionated	by	pH	 to	 reduce	 sample	


























(a)	 A	 comparison	 of	 label-free	 quantification	 (LFQ)	 intensities	 for	 each	 protein	 reveal	 a	 high	
correlation	between	technical	replicates.	(b)	A	comparison	of	LFQ	intensities	for	each	protein	in	





strategies:	 1)	 a	 standard	 parametric	 analysis	 of	 proteins	 detected	 in	 samples	 from	 both	
genotypes,	and	2)	a	nonparametric	analysis	in	which	we	asked	which	proteins	are	present	in	one	
condition	 but	 not	 the	 other	 (as	 such	 a	 categorical	 distinction	 might	 provide	 even	 greater	
biomarker	potential).		
	












Accession Symbol p-value q-value Direction 
P40142 Tkt 6.26E-08 0.0001 ↓ 
Q06335 Aplp2 2.83E-07 0.0002 ↑ 
P17182 Eno1 9.96E-07 0.0003 ↓ 
P17563 Selenbp1 1.12E-06 0.0003 ↓ 
P70296 Pebp1 1.14E-06 0.0003 ↓ 
Q06890 Clu 1.11E-06 0.0003 ↑ 
G3UYU6 Ptprd 2.47E-06 0.0005 ↑ 
O70362 Gpld1 3.30E-06 0.0005 ↑ 
P01029 C4b 2.79E-06 0.0005 ↑ 
P06909 Cfh 4.44E-06 0.0005 ↑ 
P08905 Lyz2 4.10E-06 0.0005 ↑ 
P09411 Pgk1 3.31E-06 0.0005 ↓ 
P70232 Chl1 2.69E-06 0.0005 ↑ 
P45376 Akr1b1 5.86E-06 0.0006 ↓ 
P63054 Pcp4 7.80E-06 0.0008 ↑ 
Q8VCM7 Fgg 7.99E-06 0.0008 ↓ 
A0A0R4J0X7 Gapdhs 1.05E-05 0.0009 ↓ 
H7BX99 F2 1.16E-05 0.0009 ↑ 
P08226 Apoe 1.31E-05 0.0009 ↑ 
P32848 Pvalb 1.00E-05 0.0009 ↓ 
Q9D0F9 Pgm1 1.32E-05 0.0009 ↓ 
P55065 Pltp 1.48E-05 0.001 ↑ 
A0A087WR50 Fn1 1.84E-05 0.0011 ↑ 
P08249 Mdh2 1.78E-05 0.0011 ↓ 
P97290 Serping1 1.63E-05 0.0011 ↑ 
Q61361 Bcan 1.74E-05 0.0011 ↑ 
P01887 B2m 2.25E-05 0.0012 ↑ 
P13020 Gsn 2.10E-05 0.0012 ↑ 
Q9CPU0 Glo1 2.35E-05 0.0012 ↓ 
P15626 Gstm2 3.20E-05 0.0016 ↓ 
P17183 Eno2 3.34E-05 0.0016 ↓ 
Q62000 Ogn 3.19E-05 0.0016 ↑ 
Q640N1 Aebp1 4.04E-05 0.0018 ↑ 
A0A075B664 Iglv2 4.42E-05 0.0019 ↓ 
Q03157 Aplp1 4.36E-05 0.0019 ↑ 
Q8R480 Nup85 5.36E-05 0.0022 ↓ 
P50247 Ahcy 6.07E-05 0.0025 ↓ 
E9QPX1 Col18a1 6.45E-05 0.0026 ↑ 
P21550 Eno3 7.23E-05 0.0028 ↓ 
A0A0R4J107 Apeh 7.85E-05 0.003 ↓ 
P51910 Apod 8.21E-05 0.003 ↑ 
P00920 Ca2 8.89E-05 0.0032 ↓ 
P02802 Mt1 9.13E-05 0.0032 ↓ 
P29699 Ahsg 9.68E-05 0.0033 ↑ 
Q9DCD0 Pgd 9.75E-05 0.0033 ↓ 
P12023 App 1.09E-04 0.0036 ↑ 
Q04447 Ckb 1.16E-04 0.0037 ↓ 
Q5NC80 Nme1 1.24E-04 0.0039 ↓ 
P02089 Hbb-b2 1.31E-04 0.004 ↓ 
P12960 Cntn1 1.32E-04 0.004 ↑ 
P14152 Mdh1 1.35E-04 0.004 ↓ 












We	 then	 performed	 a	 nonparametric	 analysis,	 looking	 for	 proteins	 which	 present	 in	 one	
condition	but	not	the	other,	as	such	proteins	(which	would	be	overlooked	using	standard	ANOVA	
analyses)	 could	 carry	 high	 biomarker	 potential.	 We	 first	 employed	 this	 strategy	 looking	 for	














were	 detected	 in	 at	 least	 four	 technical	 replicates	 of	 the	 wildtype	 CSF	 and	 absent	 from	 all	
knockout	replicates	and	11	proteins	 in	at	 least	 four	technical	 replicates	of	controls	but	absent	
from	all	wildtype	replicates.	Notably,	mapt	(tau)	is	present	in	only	the	retromer	knockout	CSF.		
	
4.2.2.4	Ingenuity	 Pathway	 Analysis	 (IPA)	 indicates	 APP,	 MAPT,	 and	 PSEN1	 among	 the	 top	
upstream	regulators	of	CSF	changes	in	VPS35	neuronal	knockout	mice	
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To	 further	 clarify	 the	 wealth	 of	 information	 gained	 from	 this	 CSF	 study	 (which	 includes	 52	
parametric	 hits	 and	 19	 nonparametric	 hits),	 we	 turned	 to	 ingenuity	 pathway	 analysis	 (IPA)	
(Kramer,	 Green	 et	 al.	 2014)	 to	 determine	 which	 genes	 might	 be	 ‘regulating’	 the	 global	 CSF	
changes	 in	 our	 VPS35	 knockout	model.	 This	 software	 relies	 upon	 established	 transcriptional	



















confirming	 the	 initial	mass	 spectrometry	 results	 (Figure	4.11a).	Molecular	weight	 comparison	
with	cortical	lysates	(via	immunoblot	migration)	suggests	that	these	are	indeed	the	NTFs,	not	the	
full-length	protein	(data	not	shown).	In	vitro	work	supported	these	findings,	as	levels	of	CHL1	and	







(a)	CSF	 from	a	new	cohort	of	VPS35	Camk2a	 knockout	mice	and	 littermate	controls	 reveals	a	
significant	increase	in	the	NTFs	of	BACE1	substrates	APLP1	and	CHL1,	confirming	these	hits	from	


























recombinase	 in	 VPS35fl/fl	 primary	 neurons).	 Here,	 a	 comparison	 with	 controls	 revealed	 an	









respectively.	 Values	 were	 normalized	 to	 total	 protein	 and	 then	 to	 the	 control.	 Bar	 graphs	



















CSF	 from	 mice	 (n=27)	 (a)	 and	 healthy	 control	 (n=39)	 CSF	 (b)	 reveals	 a	 striking	 correlation	
































subjects	 in	 order	 to	 identify	 all	 individuals	with	 endosomal	 dysfunction	 (both	 pre-	 and	 post-







(Ab42>210	 and	 Tau/Ab42<0.39)	 for	 AD	 (i.e.	 ‘plaque-positive’).	 Using	 this	 limited	 set,	 we	
performed	was	a	standard	t-test	of	CSF	APLP1	in	plaque-positive	AD	patients	vs	age-	and	gender-
matched	controls.	The	underlying	assumption	for	this	query	was	that	if	APLP1	is	not	sticking	to	
plaques,	 the	 levels	would	be	either	unchanged	or	elevated	 in	plaque-positive	patients	 versus	
controls.	What	we	found	instead	was	a	marked	decrease	in	the	plaque-positive	cohort	(Figure	

















mouse.	 Nonetheless,	 other	 groups	 have	 successfully	 characterized	 this	 fluid	 via	 LC-MS/MS	
(Smith,	Angel	et	al.	2014,	Dislich,	Wohlrab	et	al.	2015),	identifying	over	700	proteins	in	as	little	as	






given	 the	 number	 of	 positively	 identified	 proteins	 (1215	 in	 pooled	 replicates)	 available	 for	




mice	 (e.g.	 six	 months	 instead	 of	 three—the	 age	 used	 for	 our	 VPS35	 Camk2a	 model)	 would	
increase	the	likelihood	of	discovery	through	an	exacerbation	of	cellular	pathology.		
	
A	 second	 explanation	 for	 is	 that	 the	 VPS26a-containing	 assembly	 is	 less	 critical	 to	 trafficking	






proteins	 that	 most	 reliably	 accumulate	 in	 the	 CSF	 in	 a	 model	 of	 AD-associated	 endosomal	
dysfunction.	After	validating	the	most	relevant	proteins,	we	turned	to	human	CSF	to	investigate	
whether	the	proposed	relationship	between	these	proteins	occurs	in	the	human	brain.		The	main	









proteome	 to	 date	 (by	 roughly	 100%	 using	 a	 threshold	 of	 1	 unique	 peptide	 and	 50%	with	 a	








proteomic	 screen	 in	BACE1	KO	mice,	have	established	 that	APP,	APLP2,	APLP1,	and	CHL1	are	
substrates	 cleaved	by	BACE1	 in	 the	neuronal	 endosome,	 generating	 and	 secreting	n-terminal	
fragments	 of	 each.	 	 Our	 screen	 identified	 fragments	 of	 all	 of	 these	 proteins,	 from	which	we	
conclude	that	retromer-dependent	endosomal	dysfunction	promotes	their	accelerated	cleavage	
and	 secretion.	 	 All	 four	 of	 these	 proteins,	 including	 BACE1	 itself,	 are	 type	 I	 transmembrane	








murine	 Aβ	 is	 below	 detection	 of	 the	 methods	 used.	 	 	 Our	 human	 studies	 support	 this	
interpretation,	 suggesting	 that	 in	 plaque-free	 individuals	 a	 marker	 of	 retromer-dependent	
endosomal	dysfunction	is	positively	associated	with	CSF	Aβ.			
	
Unfortunately,	 our	 studies	 corroborate	 other	 reports	 that	 BACE1	 substrate	 NTFs	 may	 bind	





Although	 tau	 is	 known	 to	 be	 secreted	 from	 the	 endolysosomal	 pathway,	 we	 consider	 the	
observation	that	retromer-dependent	endosomal	dysfunction	causes	an	increase	in	CSF	tau	the	




are	 plaque	 free.	 	 Since	 amyloid	 plaques	 are	 avid	 binders	 of	 APP	 fragments	 and	many	 other	
 83 
extracellular	 proteins,	 it	would	 be	 interesting	 to	 probe	 the	 CSF	 of	 carriers	 of	 Sorl1	 causative	
mutations,	 in	pre-plaque	stages	of	disease.	 	Neimann-Pick	type	C1	(NPC1)	 is	a	disorder	that	 is	








commonly	exist	 in	even	normal	aging	 individuals.	 	Thus,	among	the	proteins	we	 investigated,	
elevation	 in	 CSF	 tau	 has	 the	 best	 potential	 of	 being	 a	 useful	 biomarker	 of	 AD-associated	

















order	 to	 map	 the	 full	 range	 of	 molecular	 defects	 that	 might	 regulate	 CSF	 tau.	 With	 the	
development	of	future	reagents	to	measure	not	only	total	tau,	but	levels	of	its	fragments	and	











independent	 studies	 have	 shown	 that	 mice	 bearing	 these	 mutations	 develop	 retromer-
dependent	defects	over	time	(Chu	and	Pratico	2017),	and	more	broadly	that	the	accumulation	of	
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intraneuronal	 APP	 fragments	 cause	 endosomal	 dysfunction	 (Jiang,	Mullaney	 et	 al.	 2010,	 Xu,	
Weissmiller	et	al.	2016).			
	
As	 recently	 reviewed,	endosomal	dysfunction	 represents	a	unified	cell	biological	defect	 in	AD	
(Small,	 Simoes-Spassov	et	al.	2017),	which	can	be	caused	primarily	by	molecular	defects	 that	
directly	 target	 the	 endosome,	 or	 secondarily	 via	 defects	 that	 elevate	 intraneuronal	 APP	
fragments.	 Moreover,	 evidence	 suggests	 that	 whether	 directly	 or	 indirectly,	 endosomal	
dysfunction	 can	 act	 a	 pathogenic	 hub,	 mediating	 common	 downstream	 abnormalities.	 	 Our	
results	with	retromer	knockout	mice	show,	for	the	first	time,	that	molecules	that	directly	target	
the	 endosome	 lead	 to	 established	 abnormalities	 in	 CSF	 tau.	 	 The	 prior	 studies	with	APP/PS1	
mutant	 mice	 established	 that	 increasing	 APP	 fragments	 phenocopies	 the	 same	 abnormality.	
Whether	 in	 the	 latter	 case	 this	 occurs	 through	 the	 effect	 on	 APP	 fragments	 on	 endosomal	
dysfunction,	remains	to	be	tested.		For	the	reasons	listed	above,	this	seems	highly	plausible.		If	















We	 sought	 to	 fulfill	 this	 urgent	 need	 using	 retromer	 deficiency	 as	 a	 model	 of	 AD-related	
endosomal	dysfunction.	Accordingly,	we	performed	a	battery	of	biochemical	analyses	on	CSF	and	
brain	exosomes	of	mice	with	selective	deletion	of	retromer’s	core	proteins.	Our	studies	include	
















results	 and	 our	 CSF	 proteomic	 experiments	 unearthed	more	 compelling	 leads,	 this	 lipidomic	
profile	of	non-neuronal	retromer	dysfunction	was	not	pursued	further.	
	
Possible	mechanisms	 for	 these	 changes	might	 include	mistrafficking	of	biosynthetic	enzymes.	
Neutral	sphingomyelinase,	which	converts	sphingomyelin	into	ceramide,	also	regulates	exosomal	





Exploration	 of	 two	 retromer	 knockout	models	 (full	 body	 knockout	 of	 VPS26b	 and	 forebrain-









they	 simply	 cannot	 be	 detected	 using	 current	 technology	 is	 unknown.	 Studies	 to	 clarify	 this	
question	are	warranted	in	the	pursuit	of	a	brain	exosome	biomarker.	The	former	would	impose	
a	different	strategy,	perhaps	using	serum	exosomes	in	neuronal-selective	retromer	knockouts	as	
a	 starting	 material	 for	 biomarker	 discovery	 to	 overcome	 the	 challenges	 associated	 with	








While	 these	parallels	 are	 intriguing,	 further	 clarification	of	 retromer’s	 role	 in	 these	exosomal	
biogenic	 pathways	 is	 required.	 Future	 studies	 would	 likely	 include	 electron	 microscopy	 and	

















CHL1,	 and	 APP)	 NTFs	 and	 Mapt	 (tau).	 Follow-up	 studies	 in	 vivo	 and	 in	 vitro	 confirmed	 the	
elevation	 of	 BACE1	 substrate	 NTFs	 and	 total	 tau	 in	 retromer	 knockout	 CSF.	 Interestingly,	
Ingenuity	Pathway	Analysis	positioned	these	two	categories	(APP	and	tau)	as	the	top	upstream	
‘regulators’	of	all	CSF	changes,	suggesting	their	relevance	in	the	downstream	effects	of	retromer-
dependent	 endosomal	 dysfunction.	 Follow-up	 studies	 in	 CSF	 from	 both	 mice	 and	 humans	










biomarker	 potential	 in	 early	 (pre-plaque)	 patients	 or	 in	 other	 plaque-free	 neurodegenerative	
diseases	 such	 as	 PD,	 thier	 utility	 is	 therefore	 compromised	 in	 the	 progressive	 AD	 brain.	
Accordingly,	 CSF	 total	 tau	 emerges	 as	 the	 top	 validated	 hit	 as	 a	 biomarker	 of	 AD-related	
endosomal	dysfunction	with	utility	throughout	the	course	of	disease	progression.	Remarkably,	
studies	 from	 other	 groups	 have	 shown	 that	 APP	mice,	 which	 undergo	 progressive	 retromer	
deficiency,	also	exhibit	age-related	elevations	in	CSF	total	tau		(Maia,	Kaeser	et	al.	2013).	
	
Nonetheless,	 follow-up	 studies	 are	 required	 to	 confirm	 the	 specificity	 of	 CSF	 total	 tau	 as	 a	
biomarker	of	endosomal	dysfunction	and	that	agents	which	rescue	this	cellular	deficit	reduce	CSF	
total	 tau.	 To	 address	 this	 question,	 investigations	of	other	models	of	AD-relevant	 endosomal	
dysfunction	 are	 required.	 Various	 models	 might	 include	 neuronal-selective	 knockouts	 of	
Phosphatidylinositol	3-kinase	VPS34	(Miranda,	Lasiecka	et	al.	2018)	and	mice	bearing	the	APOE4	
allele	 (Nuriel,	 Peng	 et	 al.	 2017).	 Additionally,	 treatment	with	 retromer-stabilizing	 chaperones	
(Berman,	Ringe	et	al.	2015)	or	viral	delivery	of	retromer	core	proteins	will	aid	this	mission.		
	
Post-translational	 modifications	 of	 tau	 are	 numerous	 and	 include	 various	 cleavage	 and	
phosphorylation	events.	Work	in	both	mice	and	humans	suggests	that	the	majority	of	CSF	tau	is	
at	 least	 partially	 truncated	 at	 the	 C-terminal	 (and	 perhaps	 the	 N-terminal,	 as	 well)	 (Barten,	
Cadelina	et	al.	2011,	Meredith,	Sankaranarayanan	et	al.	2013).	The	tools	we	used	in	this	study	
rely	 upon	 detection	 of	 a	 central	 epitope,	 as	 do	 standard	 assessments	 of	 CSF	 total	 tau	 in	 AD	
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patients.	 Future	 work	 to	 clarify	 the	 exact	 sequence	may	 impart	 additional	 specificity	 to	 this	






that	 the	pathways	 involved	 in	 the	 secretion	of	APLP1	NTFs	and	phosphorylated	 tau	might	be	




Although	 the	 general	 objective	 of	 this	 project	 was	 limited	 to	 biomarker	 identification,	 the	
identification	of	such	an	intriguing	and	AD-relevant	biomarker	motivates	an	increasing	interest		
in	 the	underlying	biology.	The	endolysosomal	 system	has	been	clearly	 linked	 to	 tau	secretion	
(Saman,	Kim	et	al.	2012,	Rodriguez,	Mohamed	et	al.	2017,	Caballero,	Wang	et	al.	2018).	Yet,	it	
remains	unclear	which	of	the	various	compartments	contribute	most	to	this	process.	Recent	work	














genomic	 homology.	 The	 hurdle	 is	 further	 challenged	 here	 by	 the	 presence	 of	 extracellular	
plaques	 which	 are	 known	 to	 alter	 the	 CSF	 proteome	 of	 AD	 patients.	 	 Our	 translational	
explorations	of	various	candidates	suggest	that	CSF	total	tau—unaffected	by	the	presence	of	AD	















SP,	 rabbit,	 1:500,	 R&D	 Systems),	 Tau	 (ab80579,	 mouse,	 1:500,	 Abcam),	 beta-III	 tubulin	
(ab107216,	chicken,	1:5000,	Abcam),	anti-mouse	HRP	(170-6516,	Bio-Rad),	anti-goat	HRP	(172-
1034,	 rabbit,	 1:3000,	Bio-Rad),	 anti-rabbit	HRP	 (1706515,	 goat,	 Bio-Rad),	 anti-chicken	800CW	








































Murine	CSF	was	collected	 in	a	post-mortem	procedure	 following	CO2	overdose	 in	accordance	









using	0.5uL	 in	a	1:200	dilution.	 Samples	below	0.01%	blood	contamination	were	 retained	 for	
biochemical	analyses.	For	each	assay,	both	individual	and	pooled	replicates	between	conditions	




Lipids	were	extracted	 from	equal	volumes	of	murine	CSF	 (30ul	 for	pooled	samples	or	7uL	 for	
individual	 samples).	 Lipid	 extracts	were	 prepared	 via	 chloroform-methanol	 extraction,	 spiked	
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with	appropriate	internal	standards,	and	analyzed	using	a	6490	Triple	Quadrupole	LC/MS	system	
(Agilent	 Technologies,	 Santa	 Clara,	 CA)	 as	 described	 previously(Chan,	 Oliveira	 et	 al.	 2012).	
Glycerophospholipids	 and	 sphingolipids	 were	 separated	 with	 normal-phase	 HPLC	 using	 an	














was	 pooled	 into	 four	 biological	 replicates	 per	 genotype	 of	 30uL	 each.	 Each	 replicate	 was	 a	
composite	 of	 CSF	 from	 roughly	 4-6	 mice.	 Protein	 concentrations	 from	 each	 sample	 were	
determined	 by	 a	 fluorescent-based	 protein	 assay	 (Q33211,	 Life	 Technology).	 Concentrations	
ranged	from	0.68-0.8µg/mL	per	sample.	Equal	amounts	(20μg)	from	each	sample	were	digested	
by	 trypsin	and	 labeled	with	TMT	 isobaric	mass	 tags.	A	 reference	 sample	 (comprised	of	equal	
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amounts	 from	each	sample)	was	generated	for	quantification.	After	TMT	 labeling,	all	samples	
were	 mixed	 and	 peptides	 were	 fractionated	 by	 C18	 reverse	 phase	 with	 a	 pH	 gradient	 (Life	
Technologies).	Peptide	mixtures	were	analyzed	by	Orbitrap	Fusion	Tribrid	mass	 spectrometer	
(Thermo	 Fisher)	 and	 searched	 against	 the	 mouse	 Uniprot	 protein	 database	 using	 Proteome	
Discoverer	2.1	 (Thermo	Fisher).	Overall	 intensity	of	each	TMT	channel	was	normalized	 to	 the	
reference	sample.	Minitab17	was	used	to	perform	statistical	analyses	and	generate	statistical	




High	 quality	 CSF	 (<0.01%	 blood	 contamination)	 collected	 from	 VPS35	 knockout	 and	 control	
littermates	was	pooled	into	biological	replicates	of	30uL	each,	which	were	roughly	matched	for	









detected.	Any	duplicated	protein	 identifications	 from	 the	database	were	 removed.	A	 total	of	
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1505	 mouse	 proteins	 were	 detected	 and	 included	 in	 the	 final	 data	 set.	 For	 each	 protein,	
quantification	 was	 determined	 by	 averaging	 the	 peak	 area	 of	 the	 three	most	 abundant	 and	
distinct	peptides.	Total	areas	were	used	for	normalization.	Qlucore	Omics	Explorer	and	Minitab17	
Software	were	used	 to	perform	correlation	and	 statistical	 analyses.	 Spearman	correlations	of	












in	 0.5%	 Trypsin-EDTA	 (25200056,	 Invitrogen)	 for	 20	minutes	 at	 37C.	 The	 digested	 tissue	was	
rinsed	 in	 HBSS	 and	 homogenized	 gently	 with	 a	 flame-polished	 glass	 pipette	 in	 NBA	 media	
containing	 Glutamax	 (35050-061,	 Life	 Technologies),	 B-27	 (17504044,	 Thermo	 Fisher),	 and	
pen/strep	(15140-122,	Thermo	Fisher).	Neurons	were	plated	in	six-well	plates	(83.3921,	Sarstedt)	
containing	 poly-D-lysine-coated	 12mm	 glass	 coverslips	 (NC9702891,	 Thermo	 Fisher)	 for	
immunofluorescence	 or	 in	 poly-L-ornithine-coated	 12-well	 plates	 (83.3921,	 Sarstedt)	 for	
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immunoblot	and	media	collection	experiments.	Media	was	replaced	at	24	hours	and	1/3	media	
replacements	 were	 conducted	 every	 5	 days	 thereafter.	 On	 DIV5,	 lentivirus	 containing	 either	
GFP.Cre	or	GFP.D-Cre	virus	was	added	to	each	well.	On	DIV15,	media	was	removed	and	neurons	





0792,	Bio-Rad),	boiled	 for	5	minutes	at	90C	and	 run	via	electrophoresis	 in	4-12%	bis-tris	 gels	




albumin	 (A30075-100gm,	 Research	 Product	 International)	 or	 odyssey	 blocking	 buffer	 (927-
40000,	 Licor)	 diluted	 1:1	 in	 PBS-T.	 Membranes	 were	 then	 probed	 with	 primary	 antibodies	


















CSF	 total	 tau	was	quantified	by	 SIMOA	using	 the	mouse	 total	 tau	assay	 (102209,	Quanterix).	


















early	 optimizations	 in	 control	 CSF.	 Total	 protein	 was	 calculated	 via	 BCA	 (23227,	 Pierce).	




Student’s	 t-test	was	 used	 for	 all	 biochemical	 experiments	 and	 immunohistochemical	 analysis	
using	two-tailed	distribution	with	equal	variance	(P	<	0.05).	Limma	software	was	used	for	analysis	
of	CSF	proteomics,	and	FDR-corrected	q-values	are	 reported.	Significance	 is	 indicated	as	*P	<	
0.05,	**P	<	0.01	and	***P	<	0.001;	****P	<	0.0001).	
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